Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,024Revenue $M2.9Net Margin (%)-1,579.0Z-Score14.9
Enterprise Value $M804EPS $-0.7Operating Margin %-1,701.9F-Score2
P/E(ttm))0Cash Flow Per Share $0.7Pre-tax Margin (%)-1,579.0Higher ROA y-yN
Price/Book4.010-y EBITDA Growth Rate %0Quick Ratio20.9Cash flow > EarningsY
Price/Sales4115-y EBITDA Growth Rate %0Current Ratio20.9Lower Leverage y-yN
Price/Cash Flow10.0y-y EBITDA Growth Rate %0ROA % (ttm)-29.8Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-38.3Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M75.9ROI % (ttm)-12.8Gross Margin Increase y-yN

Gurus Latest Trades with NBIX

Number of guru portfolios checked: 56.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
NBIXGeorge Soros 2013-09-30 Sold Out -0.03%$10.6 - $16.7
($13.79)
$ 13.67-1%Sold Out0
NBIXGeorge Soros 2013-06-30 Buy 0.03%$10.9 - $13.57
($12.28)
$ 13.6711%New holding, 200000 sh.200,000
NBIXJoel Greenblatt 2012-12-31 Sold Out -0.13%$6.88 - $8.66
($7.6)
$ 13.6780%Sold Out0
NBIXJoel Greenblatt 2012-06-30 Add0.03%$6.31 - $8.06
($7.18)
$ 13.6790%Add 23.8%259,903
NBIXGeorge Soros 2012-06-30 Sold Out -0.02%$6.31 - $8.06
($7.18)
$ 13.6790%Sold Out0
NBIXJoel Greenblatt 2012-03-31 Buy 0.15%$7.33 - $9.79
($7.95)
$ 13.6772%New holding, 209930 sh.209,930
NBIXGeorge Soros 2012-03-31 Buy 0.02%$7.33 - $9.79
($7.95)
$ 13.6772%New holding, 150000 sh.150,000
NBIXGeorge Soros 2011-12-31 Sold Out -0.0018%$5.5 - $8.58
($6.76)
$ 13.67102%Sold Out0
NBIXGeorge Soros 2011-09-30 Reduce$5.59 - $8.44
($6.71)
$ 13.67104%Reduce -23.93%17,800
NBIXGeorge Soros 2011-06-30 Add$6.82 - $8.3
($7.54)
$ 13.6781%Add 90.24%23,400
NBIXGeorge Soros 2011-03-31 Add$6.47 - $7.84
($7.2)
$ 13.6790%Add 23%12,300
NBIXGeorge Soros 2010-12-31 Buy $5.99 - $8.53
($7.63)
$ 13.6779%New holding, 10000 sh.10,000
NBIXGeorge Soros 2008-06-30 Sold Out -0.01%$4.28 - $5.86
($5)
$ 13.67173%Sold Out0
NBIXGeorge Soros 2008-03-31 Buy 0.01%$4.51 - $5.58
($5.1)
$ 13.67168%New holding, 21038 sh.21,038
NBIXGeorge Soros 2007-12-31 Sold Out -0.01%$4.4 - $13.02
($9)
$ 13.6752%Sold Out0
NBIXGeorge Soros 2007-09-30 Add$9.69 - $11.88
($10.6)
$ 13.6729%Add 61.87%20,362
NBIXGeorge Soros 2007-06-30 Buy $11.39 - $14.14
($12.4)
$ 13.6710%New holding, 12579 sh.12,579
NBIXGeorge Soros 2006-12-31 Sold Out -0.02%$7.72 - $12.55
($10.2)
$ 13.6734%Sold Out0
NBIXGeorge Soros 2006-09-30 Buy 0.02%$8.91 - $10.93
($10.1)
$ 13.6735%New holding, 35000 sh.35,000
NBIXGeorge Soros 2006-03-31 Buy 0.23%$59.43 - $70.41
($64.8)
$ 13.67-79%New holding, 100000 sh.100,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

NBIX is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


NBIX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Bozigian Haig P.CHIEF DEVELOPMENT OFFICER 2014-01-17Sell25,000$20-31.65 view
Grigoriadis Dimitri E.CHIEF RESEARCH OFFICER 2014-01-17Sell25,000$20-31.65 view
Coughlin Timothy PCFO 2014-01-10Sell1,750$18.56-26.35 view
GORMAN KEVIN CHARLESPresident and CEO 2014-01-10Sell3,750$18.57-26.39 view
OBrien Christopher FlintChief Medical Officer 2014-01-10Sell6,750$18.88-27.6 view
Grigoriadis Dimitri E.Chief Research Officer 2014-01-10Sell1,625$18.56-26.35 view
Bozigian Haig P.Chief Development Officer 2014-01-10Sell1,625$18.58-26.43 view
Gano KyleChief Business Dev Officer 2014-01-10Sell1,250$18.57-26.39 view
Coughlin Timothy PCFO 2014-01-07Sell70,000$16.75-18.39 view
OBrien Christopher FlintChief Medical Officer 2014-01-07Sell5,000$17.5-21.89 view

Press Releases about NBIX :

    Quarterly/Annual Reports about NBIX:

    News about NBIX:

    Articles On GuruFocus.com
    Weekly Insider Sells Highlight: ORCL, TWC, FB, NBIX Jan 13 2014 
    5 Strong Healthcare Stocks For 2012 Mar 24 2012 
    Consider These 5 Healthcare Stocks Now Mar 21 2012 
    Neurocrine Biosciences Inc. (NBIX) VP and CFO Timothy P Coughlin sells 12,320 Shares Mar 02 2011 
    Neurocrine Biosciences Inc. (NBIX) President and CEO Kevin Charles Gorman sells 15,400 Shares Mar 02 2011 
    Neurocrine Biosciences Inc. Reports Operating Results (10-Q) Oct 29 2010 
    Neurocrine Biosciences Inc. Reports Operating Results (10-Q) Jul 29 2010 
    Neurocrine Biosciences Inc. Reports Operating Results (10-Q) Apr 29 2010 
    Neurocrine Biosciences Inc. (NBIX) VP and CFO Timothy P Coughlin sells 12,650 Shares Mar 03 2010 
    Neurocrine Biosciences Inc. (NBIX) President and CEO Kevin Charles Gorman sells 15,609 Shares Mar 03 2010 

    More From Other Websites
    2 Biotechs Race To Treat Movement Disorders Jun 27 2014
    Neurocrine In "Hurry Up And Wait" Mode Jun 11 2014
    Neurocrine Biosciences Presenting NBI-98854 Scientific Abstracts And Posters At The International... Jun 11 2014
    Neurocrine Biosciences To Present At The Jefferies 2014 Global Healthcare Conference May 29 2014
    NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 22 2014
    Neurocrine Biosciences' (NBIX) CEO Kevin Gorman Presents at Bank of America Merrill Lynch 2014... May 15 2014
    Neurocrine Biosciences' (NBIX) CEO Kevin Gorman on Deutsche Bank 39th Annual Health Care Conference... May 10 2014
    NEUROCRINE BIOSCIENCES INC Financials May 09 2014
    Neurocrine Biosciences to Present at the Bank of America Merrill Lynch 2014 Health Care Conference May 08 2014
    NEUROCRINE BIOSCIENCES INC Files SEC form 10-Q, Quarterly Report May 01 2014
    Neurocrine Biosciences to Present at Deutsche Bank's 39th Annual Health Care Conference May 01 2014
    Neurocrine Biosciences' CEO Discusses Q1 2014 Results - Earnings Call Transcript Apr 30 2014
    NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Results of Operations and Financial Condition,... Apr 30 2014
    Neurocrine Biosciences Reports First Quarter 2014 Results Apr 30 2014
    Q1 2014 Neurocrine Biosciences Earnings Release - After Market Close Apr 30 2014
    Neurocrine Biosciences Announces Conference Call And Webcast To Report First Quarter 2014 Financial... Apr 25 2014
    Commit To Purchase Neurocrine Biosciences At $11, Earn 23.9% Annualized Using Options Apr 07 2014
    Neurocrine Biosciences To Present At The 26th Annual Roth Conference Mar 04 2014
    Neurocrine Biosciences To Present At The 26th Annual Roth Conference Mar 04 2014

    Add Notes, Comments or Ask Questions

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK
    Email Hide